[go: up one dir, main page]

NO20031744L - Nye ikke-imadazolforbindelser og farmasöytisk preparat omfattende slike - Google Patents

Nye ikke-imadazolforbindelser og farmasöytisk preparat omfattende slike

Info

Publication number
NO20031744L
NO20031744L NO20031744A NO20031744A NO20031744L NO 20031744 L NO20031744 L NO 20031744L NO 20031744 A NO20031744 A NO 20031744A NO 20031744 A NO20031744 A NO 20031744A NO 20031744 L NO20031744 L NO 20031744L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
new non
imadazole
compounds
imadazole compounds
Prior art date
Application number
NO20031744A
Other languages
English (en)
Other versions
NO20031744D0 (no
NO325997B1 (no
Inventor
Robert G Aslanian
Neng-Yang Shih
Pauline C Ting
Michael Y Berlin
Stuart B Rosenblum
Kevin D Mccormick
Wing C Tom
Christopher W Boyce
Pietro Mangiaracina
Mwangi Wa Mutahi
John J Piwinski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20031744D0 publication Critical patent/NO20031744D0/no
Publication of NO20031744L publication Critical patent/NO20031744L/no
Publication of NO325997B1 publication Critical patent/NO325997B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
NO20031744A 2000-10-17 2003-04-15 Piperidinforbindelser og anvendelse derav NO325997B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24090100P 2000-10-17 2000-10-17
PCT/US2001/032151 WO2002032893A2 (en) 2000-10-17 2001-10-15 Piperidine compounds as anti-allergic

Publications (3)

Publication Number Publication Date
NO20031744D0 NO20031744D0 (no) 2003-04-15
NO20031744L true NO20031744L (no) 2003-06-14
NO325997B1 NO325997B1 (no) 2008-09-01

Family

ID=22908389

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031744A NO325997B1 (no) 2000-10-17 2003-04-15 Piperidinforbindelser og anvendelse derav

Country Status (30)

Country Link
US (3) US6720328B2 (no)
EP (2) EP1326858B1 (no)
JP (2) JP4093859B2 (no)
KR (1) KR100567266B1 (no)
CN (2) CN1803795B (no)
AR (1) AR035497A1 (no)
AT (2) ATE312833T1 (no)
AU (2) AU2002215355B2 (no)
BR (1) BR0114754A (no)
CA (1) CA2424664C (no)
CY (2) CY1105227T1 (no)
DE (2) DE60115937T2 (no)
DK (2) DK1571145T3 (no)
EC (1) ECSP034559A (no)
ES (2) ES2320008T3 (no)
HK (2) HK1052935B (no)
HU (1) HUP0303835A3 (no)
IL (1) IL155031A0 (no)
MX (1) MXPA03003529A (no)
NO (1) NO325997B1 (no)
NZ (1) NZ524857A (no)
PE (1) PE20020507A1 (no)
PL (1) PL361978A1 (no)
PT (1) PT1571145E (no)
RU (2) RU2301231C2 (no)
SI (1) SI1326858T1 (no)
SK (1) SK4672003A3 (no)
TW (2) TWI258474B (no)
WO (1) WO2002032893A2 (no)
ZA (1) ZA200302521B (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
AU2002244271A1 (en) * 2001-03-13 2002-09-24 Pharmacopeia, Inc. Non-imidazole compounds as histamine h3 antagonists
AR036881A1 (es) * 2001-10-15 2004-10-13 Schering Corp Un proceso para la preparacion de 4-(piperidil)(2-piridil)metanona-(e)-o-metiloxima y sales
PE20040464A1 (es) 2002-04-18 2004-07-24 Schering Corp Benzimidazolonas sustituidas y derivados como antagonistas de histamina h3
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
DK1539742T3 (da) 2002-06-24 2006-12-27 Schering Corp Indolderivater, der er nyttige som histamin H3-antagonister
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
EP2194058B1 (en) 2002-09-04 2013-11-27 Merck Sharp & Dohme Corp. Pyrazolopyrimidines suitable for the treatment of cancer diseases
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AU2004205642C1 (en) 2003-01-14 2012-01-12 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
WO2004066960A2 (en) * 2003-01-28 2004-08-12 Schering Corporation Combination of h1, h3 and h4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
PT1615909E (pt) 2003-04-23 2008-10-30 Glaxo Group Ltd Derivados de piperazina e a sua utilização para o tratamento de doenças neurológicas e psiquiátricas
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005014571A1 (en) * 2003-07-18 2005-02-17 Glaxo Group Limited Substituted piperidines as histamine h3 receptor ligands
US20060030550A1 (en) * 2004-08-04 2006-02-09 Lithgow Theodore L Pharmaceutical formulations
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
JP2008546784A (ja) * 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
CA2609957A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists
WO2007035703A1 (en) 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
WO2007075555A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
WO2007075688A2 (en) 2005-12-21 2007-07-05 Schering Corporation Substituted aniline derivatives useful as histamine h3 antagonists
CA2634250A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
WO2007075702A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
US7897601B2 (en) 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
EP2136805A2 (en) * 2007-03-02 2009-12-30 Schering Corporation Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
EP2170846A2 (en) * 2007-06-28 2010-04-07 Intervet International BV Substituted piperazines as cb1 antagonists
BRPI0818626A2 (pt) * 2007-10-17 2015-09-29 Sanofi Aventis n-fenil-bipirrolidina carboxamidas substituída e uso terapêutico da mesma
NZ584691A (en) * 2007-10-17 2011-09-30 Sanofi Aventis Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
RU2477720C2 (ru) * 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их применение в лечебных целях
PL2215058T3 (pl) * 2007-10-17 2012-04-30 Sanofi Sa Podstawione N-fenylo-bipirolidynomoczniki oraz ich zastosowanie terapeutyczne
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
CA2739668C (en) * 2008-01-04 2016-10-11 Schabar Research Associates Llc The use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
WO2010027567A2 (en) 2008-07-23 2010-03-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
EP2350048A2 (en) 2008-10-16 2011-08-03 Schering Corporation Azine derivatives and methods of use thereof
US20110245267A1 (en) 2008-12-19 2011-10-06 Schering Plough Corporation Piperidine and piperazine derivatives and methods of use thereof
US8283360B2 (en) 2008-12-19 2012-10-09 Merck Sharp & Dohme Corp. Bicyclic heterocyclic derivatives and methods of use thereof
ES2486674T3 (es) * 2009-04-22 2014-08-19 Janssen Pharmaceutica N.V. Piperazinilazetidinilamidas heteroaromáticas y aromáticas como inhibidores de la monoacilglicerol lipasa
MX2011013679A (es) 2009-06-16 2012-01-20 Schering Corp Esteroides de heteroarilo [3.2-c] novedosos como agonistas de receptor de glucocorticoide composiciones y uso de los mismos.
PT2473049T (pt) 2009-09-04 2019-03-04 Sunesis Pharmaceuticals Inc Inibidores de tirosina quinase de bruton
MY161134A (en) * 2010-01-22 2017-04-14 Taiho Pharmaceutical Co Ltd Piperazine compound having a pgds inhibitory effect
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN105315267B (zh) * 2014-07-30 2019-06-04 江苏恩华药业股份有限公司 一种酰胺类衍生物及其应用
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
BR112019001158A2 (pt) 2016-07-21 2019-04-30 Biogen Ma, Inc. formas de succinato e composições de inibidores da tirosina quinase de bruton
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
BR112020024762A2 (pt) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
CN110105263A (zh) * 2019-05-13 2019-08-09 常州大学 一种阿米卡星中间体的合成方法
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
AU2021310264A1 (en) 2020-07-15 2023-02-09 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407217A1 (en) 1989-07-07 1991-01-09 Schering Corporation Pharmaceutically active compounds
US5633250A (en) 1991-12-18 1997-05-27 Schering Corporation Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
MY110108A (en) 1991-12-18 1998-01-27 Schering Corp Imidazolyl or imidazolylalkyl substituted with a four or five membered nitrigen containing heterocyclic ring
US5807872A (en) 1992-12-16 1998-09-15 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
ATE232858T1 (de) * 1995-11-17 2003-03-15 Aventis Pharma Inc Substituierte 4-(1h-benzimidazol-2-yl- amino)piperidine zur behandlung allergischer erkrankungen
ATE314071T1 (de) 1996-08-16 2006-01-15 Schering Corp Behandlung von allergischen reaktionen im oberen respirationstrakt mit einer kombination von histamin-rezeptor-antagonisten
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US5990147A (en) 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
DE69806042T2 (de) 1997-11-07 2003-01-23 Schering Corp., Kenilworth Phenylalkyl imidazole derivate als h3 rezeptor liganden
US6034251A (en) 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
CA2346227A1 (en) * 1998-10-09 2000-04-20 Schering Corporation Composition and method for treating allergic diseases
US6100279A (en) 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2002244271A1 (en) 2001-03-13 2002-09-24 Pharmacopeia, Inc. Non-imidazole compounds as histamine h3 antagonists
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
PE20040464A1 (es) * 2002-04-18 2004-07-24 Schering Corp Benzimidazolonas sustituidas y derivados como antagonistas de histamina h3
DK1539742T3 (da) * 2002-06-24 2006-12-27 Schering Corp Indolderivater, der er nyttige som histamin H3-antagonister
US20040198743A1 (en) * 2003-01-31 2004-10-07 Schering Corporation Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists

Also Published As

Publication number Publication date
TWI292399B (en) 2008-01-11
US20030045519A1 (en) 2003-03-06
NO20031744D0 (no) 2003-04-15
DE60115937T2 (de) 2006-06-29
DE60115937D1 (de) 2006-01-19
JP4093859B2 (ja) 2008-06-04
DK1571145T3 (da) 2009-05-04
ATE312833T1 (de) 2005-12-15
CN1243751C (zh) 2006-03-01
HUP0303835A3 (en) 2009-08-28
CN1803795A (zh) 2006-07-19
JP2007145866A (ja) 2007-06-14
PT1571145E (pt) 2009-04-07
US7300941B2 (en) 2007-11-27
CA2424664A1 (en) 2002-04-25
ECSP034559A (es) 2003-06-25
MXPA03003529A (es) 2003-08-07
KR20030036931A (ko) 2003-05-09
EP1571145B1 (en) 2009-01-14
HUP0303835A2 (hu) 2004-03-01
ES2320008T3 (es) 2009-05-18
HK1081182A1 (en) 2006-05-12
ATE420863T1 (de) 2009-01-15
AR035497A1 (es) 2004-06-02
WO2002032893A3 (en) 2002-08-22
AU2002215355B2 (en) 2006-09-14
PL361978A1 (en) 2004-10-18
CA2424664C (en) 2008-12-23
HK1052935B (zh) 2006-05-19
NZ524857A (en) 2004-12-24
KR100567266B1 (ko) 2006-04-03
EP1326858A2 (en) 2003-07-16
PE20020507A1 (es) 2002-06-25
CY1110262T1 (el) 2015-01-14
TW200510368A (en) 2005-03-16
US20040097513A1 (en) 2004-05-20
EP1326858B1 (en) 2005-12-14
EP1571145A1 (en) 2005-09-07
IL155031A0 (en) 2003-10-31
SK4672003A3 (en) 2003-11-04
RU2007104096A (ru) 2008-08-10
JP2004511553A (ja) 2004-04-15
CY1105227T1 (el) 2010-03-03
US20080119487A1 (en) 2008-05-22
ES2250500T3 (es) 2006-04-16
DK1326858T3 (da) 2006-05-08
ZA200302521B (en) 2004-06-30
NO325997B1 (no) 2008-09-01
DE60137461D1 (de) 2009-03-05
CN1469873A (zh) 2004-01-21
HK1052935A1 (en) 2003-10-03
RU2301231C2 (ru) 2007-06-20
WO2002032893A2 (en) 2002-04-25
AU1535502A (en) 2002-04-29
SI1326858T1 (sl) 2006-04-30
US6720328B2 (en) 2004-04-13
TWI258474B (en) 2006-07-21
BR0114754A (pt) 2003-07-01
CN1803795B (zh) 2010-05-12

Similar Documents

Publication Publication Date Title
NO20031744L (no) Nye ikke-imadazolforbindelser og farmasöytisk preparat omfattende slike
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
NO20030418L (no) Nytt farmasöytisk preparat
DK1263721T3 (da) Farmaceutiske sammensætninger, der indeholder 3-aminoazetidinderivater, nye derivater og fremstilling deraf
NO20025450L (no) Ny farmasöytisk sammensetning
DK1524266T3 (da) Farmaceutisk sammensætning
FI20011478L (fi) Farmaseuttinen koostumus
NO20033143D0 (no) Farmasoytisk preparat
NO20033002D0 (no) Nye kinuklidinderivater og medisinske sammensetninger inneholdende det samme
ITMI20010748A0 (it) Composizioni farmaceutiche
NO20033715L (no) Nye sammensetninger
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20055652D0 (no) Laktatinneholdende farmasoytisk preparat og anvendelse av dette
EE05020B1 (et) Glburiidi ravimkoostis
DK1429769T3 (da) Nye formuleringer og anvendelse deraf
NO20015074L (no) Nye sammensetninger
EE200300589A (et) Ravimkoostised
NO20034695D0 (no) Nye sammensetninger
NO20040996L (no) Nye forbindelser og sammensetninger som catepsin-inhibitorer
FI20022128L (fi) Farmaseuttinen koostumus
NO20031095D0 (no) Farmasöytiske sammensetninger
NO20030156D0 (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
NO20030822L (no) Nye forbindelser og fremgangsmåter

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees